Elicio Therapeutics, Inc. Receivables, Net, Current
Elicio Therapeutics, Inc. (ELTX) had Receivables, Net, Current of $9.68 million as of 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesNetCurrent · last filed 2023-05-10
- 2023-03-31: Receivables, Net, Current $9.68M.
- 2022-12-31: Receivables, Net, Current $0.00.
| Period end | Receivables, Net, Current |
|---|---|
| 2023-03-31 | $9.68M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |